Economic Implications of the Use of Basiliximab in Addition to Triple Immunosuppressive Therapy in Renal Allograft Recipients
- 1 January 2003
- journal article
- clinical trial
- Published by Springer Nature in PharmacoEconomics
- Vol. 21 (2) , 129-138
- https://doi.org/10.2165/00019053-200321020-00005
Abstract
No abstract availableKeywords
This publication has 16 references indexed in Scilit:
- The economics of basiliximab (Simulect) in preventing acute rejection in renal transplantationTransplant International, 2002
- An economic and quality‐of‐life assessment of basiliximab vs antithymocyte globulin immunoprophylaxis in renal transplantationNephrology Dialysis Transplantation, 2001
- Improved Graft Survival after Renal Transplantation in the United States, 1988 to 1996New England Journal of Medicine, 2000
- REDUCTION OF THE OCCURRENCE OF ACUTE CELLULAR REJECTION AMONG RENAL ALLOGRAFT RECIPIENTS TREATED WITH BASILIXIMAB, A CHIMERIC ANTI-INTERLEUKIN-2-RECEPTOR MONOCLONAL ANTIBODY1,2Transplantation, 1999
- The provision of renal replacement therapy for adults in England and Wales: recent trends and future directionsQJM: An International Journal of Medicine, 1998
- Randomised trial of basiliximab versus placebo for control of acute cellular rejection in renal allograft recipientsThe Lancet, 1997
- DETERMINANTS OF GRAFT SURVIVAL AFTER RENAL TRANSPLANTATION1Transplantation, 1996
- PROLONGED ACTION OF A CHIMERIC INTERLEUKIN-2 RECEPTOR (CD25) MONOCLONAL ANTIBODY USED IN CADAVERIC RENAL TRANSPLANTATIONTransplantation, 1995
- Cost-Effectiveness Studies of Renal TransplantationInternational Journal of Technology Assessment in Health Care, 1995
- Causes of Late Renal Allograft Failure in the Ciclosporin EraNephron, 1992